Injective rises as official USDC and CCTP integration confirmed for May 8, 2026

Traders Union
All News
Crypto
Injective gains 7.10% today on news

Highlights

Injective integrated USDC and Circle's Cross-Chain Transfer Protocol, significantly enhancing stablecoin support and cross-chain liquidity on its network.
The upgrade triggered immediate adoption, with daily trading volume surging to $141.80 million and market capitalization reaching $409.94 million.
Technical indicators reflect short-term bullish momentum but overbought conditions suggest INJ will likely consolidate sideways within a $4.10–$4.50 range.

Stablecoin integration lifts network activity and DeFi flows

Injective has gained attention following the official launch of USDC and Circle's Cross-Chain Transfer Protocol (CCTP) on its network, an event confirmed by Circle on May 8, 2026. The new integration directly enhances Injective’s ecosystem by providing robust stablecoin support, deepening cross-chain liquidity, and facilitating more efficient USDC transfers for DeFi users. This has led to an immediate jump in network activity with daily trading volume reaching $141.80 million and market capitalization expanding to approximately $409.94 million, underscoring swift adoption and impact from the protocol upgrade.

Bullish momentum persists as indicators warn of overbought risk

On the technical front, INJ is trading above the MA-20 ($3.59) and MA-50 ($3.22), but remains below the MA-200 ($4.53). The Ichimoku Kijun level at $3.59 offers nearby support, while resistance is clearly defined at the MA-200. Momentum indicators such as MACD and ADX on the daily chart confirm ongoing bullish strength. However, overbought signals from the RSI (72.8), CCI (171.32), and Stoch RSI, alongside a high BBP reading (0.55), point to stretched short-term conditions and the possibility of a corrective pullback.

Consolidation likely as overbought signals cap upside potential

Over the next five trading days, INJ is likely to consolidate within a typical volatility band between $4.10 and $4.50. The probability of further price gains is low (less than 20%), with a higher chance of a pullback as overbought conditions are worked off. If the price rises above $4.50, a breakout scenario is possible, though the MA-200 presents notable resistance. Conversely, a decline below immediate support at $3.59 could trigger a more pronounced move down toward the medium-term moving averages.

Viktoras Karapetjanc, expert at Traders Union, sees USDC and Circle’s CCTP launch as a major step for Injective’s ecosystem. He notes the immediate spike in trading volume and market cap shows clear positive sentiment and strong adoption. However, he remains watchful of overbought conditions despite bullish momentum. In his view, further gains need a clean break above $4.50 to confirm the next leg up. "As long as user activity stays elevated and key support holds, I believe the risk-reward for Injective remains attractive in the short term."

Earlier, analysts noted that Injective was exhibiting renewed bullish momentum, while cautioning that overbought signals could lead to a short-term pullback. With fresh ecosystem upgrades now driving both adoption and trading activity, traders should closely monitor for a potential breakout above the MA-200, as sustained gains may hinge on overcoming this key resistance.

Source of Data: INJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.